Abstract
Tribbles-related protein (TRB) family members are the mammalian orthologs of Drosophila tribbles. Tribbles was originally identified as a cell cycle regulator during Drosophila development. Tribbles genes are evolutionary conserved, and three TRB genes (TRB1, TRB2 and TRB3) have been identified in mammals. TRBs are considered pseudokinases because they lack an ATP binding site or one of the conserved catalytic motifs essential for kinase activity. Instead, TRBs play important roles in various cellular processes as scaffolds or adaptors to promote the degradation of target proteins and to regulate several key signaling pathways. Recent research has focused on the role of TRBs in tumorigenesis and neoplastic progression. In this review, we focus on the physiological roles of TRB family members in tumorigenesis through the regulation of the ubiquitin-proteasome system and discuss TRBs as biomarkers or potential therapeutic targets in cancer.
Keywords: Leukemogenesis, oncogene, TRB1, TRB2, TRB3, tumorigenesis, ubiquitin-proteasome system.
Current Cancer Drug Targets
Title:Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Volume: 16 Issue: 2
Author(s): Satoshi Sakai, Chiharu Miyajima, Chiharu Uchida, Yuka Itoh, Hidetoshi Hayashi and Yasumichi Inoue
Affiliation:
Keywords: Leukemogenesis, oncogene, TRB1, TRB2, TRB3, tumorigenesis, ubiquitin-proteasome system.
Abstract: Tribbles-related protein (TRB) family members are the mammalian orthologs of Drosophila tribbles. Tribbles was originally identified as a cell cycle regulator during Drosophila development. Tribbles genes are evolutionary conserved, and three TRB genes (TRB1, TRB2 and TRB3) have been identified in mammals. TRBs are considered pseudokinases because they lack an ATP binding site or one of the conserved catalytic motifs essential for kinase activity. Instead, TRBs play important roles in various cellular processes as scaffolds or adaptors to promote the degradation of target proteins and to regulate several key signaling pathways. Recent research has focused on the role of TRBs in tumorigenesis and neoplastic progression. In this review, we focus on the physiological roles of TRB family members in tumorigenesis through the regulation of the ubiquitin-proteasome system and discuss TRBs as biomarkers or potential therapeutic targets in cancer.
Export Options
About this article
Cite this article as:
Sakai Satoshi, Miyajima Chiharu, Uchida Chiharu, Itoh Yuka, Hayashi Hidetoshi and Inoue Yasumichi, Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122645
DOI https://dx.doi.org/10.2174/1568009616666151112122645 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Genes of Human Longevity: An Endless Quest?
Current Vascular Pharmacology Kinase Inhibitors in Multitargeted Cancer Therapy
Current Medicinal Chemistry From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design In Silico Transcriptomic Analysis of the Chloride Intracellular Channels (CLIC) Interactome Identifies a Molecular Panel of Seven Prognostic Markers in Patients with Pancreatic Ductal Adenocarcinoma
Current Genomics The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry The Potential Role of Peritumoral Apparent Diffusion Coefficient Evaluation in Differentiating Glioblastoma and Solitary Metastatic Lesions of the Brain
Current Medical Imaging Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)